AnaptysBio holds ANB033 (CD122 antagonist) investor event; updates corporate presentation

ANAPTYSBIO, INC

Conference call and slide presentation on ANB033 (CD122 antagonist) held on October 14, 2025.
Updated corporate investor presentation filed as Exhibit 99.2; no specific clinical or financial data disclosed in the filing text.
Event intended to provide pipeline update; details of ANB033 discussion not expanded in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.